Wenfei Yu
Overview
Explore the profile of Wenfei Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Yu H, Wang D, Yin G, Chen S, Zhang X, et al.
J Nutr Biochem
. 2025 Mar;
:109886.
PMID: 40023201
Background: The most prevalent liver condition globally is non-alcoholic fatty liver disease (NAFLD), for which no approved therapies currently exist. Diosgenin, an important component in plants from the Leguminosae, Dioscoreaceae,...
2.
Liu F, Yang Z, Li J, Wu T, Li X, Zhao L, et al.
Mol Med
. 2024 Dec;
30(1):265.
PMID: 39707216
Diabetic kidney disease (DKD), one of the most prevalent microvascular complications of diabetes, arises from dysregulated glucose and lipid metabolism induced by hyperglycemia, resulting in the deterioration of renal cells...
3.
Ma K, Miao L, Li B, Yu W, Liu F, Liu K, et al.
J Orthop Surg Res
. 2024 Nov;
19(1):759.
PMID: 39543632
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis that can lead to joint deformities. To date, more than 18 million individuals worldwide have been diagnosed with RA, making...
4.
Yin G, Liang H, Cheng Y, Chen S, Zhang X, Meng D, et al.
Chem Biol Interact
. 2024 Nov;
405:111306.
PMID: 39536891
Excessive hepatic lipid accumulation and inflammatory injury are significant pathological manifestations of nonalcoholic fatty liver disease (NAFLD). Our previous research discovered that diosgenin, a natural steroidal saponin derived from Chinese...
5.
Chen S, Lu H, Yin G, Zhang X, Meng D, Yu W, et al.
Biochim Biophys Acta Mol Cell Biol Lipids
. 2024 Oct;
1870(1):159570.
PMID: 39454819
Non-alcoholic fatty liver disease (NAFLD) is becoming a global public health burden, yet effective therapeutic strategies are notably lacking. NAFLD development may be mediated by mitochondrial dysfunction, according to new...
6.
Zhang X, Yin G, Chen S, Meng D, Yu W, Liu H, et al.
Diabetes Obes Metab
. 2024 Sep;
26(12):5745-5756.
PMID: 39344834
Aim: This study aimed to investigate the mechanisms through which diosgenin inhibits the pathogenesis of non-alcoholic fatty liver disease, focusing particularly on ferroptosis-related pathways and its reliance on nuclear factor...
7.
Yu W, Zhang F, Meng D, Zhang X, Feng Y, Yin G, et al.
Curr Drug Deliv
. 2024 Jul;
21(10):1300-1319.
PMID: 39034715
With the acceleration of people's pace of life, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world, which greatly threatens people's health and...
8.
Yu W, Yin G, Chen S, Zhang X, Meng D, Wang L, et al.
Int Immunopharmacol
. 2024 Jun;
138:112581.
PMID: 38944952
Metabolic-associated fatty liver disease (MAFLD) is one of the most common liver diseases worldwide; however, its pathogenesis and treatment methods have not been perfected. NOD-like receptor thermal protein domain-associated protein...
9.
Liu H, Li Y, Jin Y, Li X, Wang D, Yu X, et al.
Phytother Res
. 2024 Jun;
38(7):3801-3824.
PMID: 38886838
Due to a scarcity of appropriate therapeutic approaches capable of ameliorating or eliminating non-alcoholic fatty liver disease (NAFLD), many researchers have come to focus on natural products based on traditional...
10.
Meng D, Yin G, Chen S, Zhang X, Yu W, Wang L, et al.
Eur J Pharmacol
. 2024 Jun;
977:176737.
PMID: 38866362
The prevalence of nonalcoholic fatty liver disease (NAFLD) has been increasing worldwide in recent years, causing severe economic and social burdens. Therefore, the lack of currently approved drugs for anti-NAFLD...